Welcome to our dedicated page for SBC Medical Group Holdings Incorporated SEC filings (Ticker: SBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SBC Medical Group Holdings Incorporated (Nasdaq: SBC) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer with associated redeemable warrants trading under the symbol SBCWW, SBC submits a range of filings that document its financial condition, material events, and capital markets activity.
Among the most relevant documents for investors are current reports on Form 8-K, which SBC uses to announce material events such as quarterly financial results, tender offers and acquisitions, index inclusions, and capital strategy updates. For example, the company has filed 8-K reports to furnish press releases on quarterly results, to describe its inclusion in the Russell 3000 Index, and to summarize a tender offer for shares of Waqoo, Inc., a regenerative medicine research and development company. These filings provide detail on SBC’s operating performance, investment activities, and strategic direction.
Investors can also review filings related to capital structure and financing, including registration statements such as the company’s shelf registration on Form S-3. That registration statement, referenced in SBC’s news releases and 8-K filings, enables the company to offer and sell specified amounts of common and preferred stock in future offerings and also covers securities associated with its prior business combination transaction.
On Stock Titan, SBC’s filings are complemented by AI-powered summaries designed to help readers interpret complex regulatory documents. These summaries highlight key points from lengthy filings, such as the nature of material events disclosed in Form 8-K, the scope of registered securities in shelf filings, and the implications of tender offers or strategic investments. The page updates as new SBC filings are posted to the SEC’s EDGAR system, giving users a centralized view of the company’s regulatory history and ongoing disclosure record.
SBC Medical Group Holdings filed Amendment No. 1 to its 2025 annual report to add detailed Part III disclosures on directors, executive compensation, ownership and related‑party transactions. The amendment also updates the April 29, 2026 outstanding share count to 102,576,943 and clarifies that no information is incorporated by reference. It does not change previously reported 2025 financial results.
The filing shows CEO Yoshiyuki Aikawa controls about 81.7% of voting power and received a $12,000,000 base salary in 2025. SBC describes its board committees, controlled‑company status under Nasdaq rules, employment agreements with key executives, and extensive revenue and financing relationships with Japanese medical corporations and other entities related to the CEO and his family.
SBC Medical Group Holdings Inc Chairman and CEO Yoshiyuki Aikawa reported an open-market sale of 465,000 shares of common stock on April 28, 2026 at a net price of $3.0225 per share. The sale occurred on the closing date of the underwriters' option to purchase additional shares tied to an underwritten public offering that initially closed on April 21, 2026.
Following the transaction, Aikawa holds 78,839,460 SBC shares directly, plus indirect interests including 5,000,000 shares held by Aikawa Investment Co., Ltd., which he wholly owns, and an 861,600-share indirect interest through Aikawa Equity Management Co., Ltd., where he disclaims beneficial ownership except for his pecuniary interest.
SBC Medical Group Holdings Inc Chairman and CEO Yoshiyuki Aikawa sold 3,100,000 shares of common stock at a net price of $3.0225 per share in an underwritten public offering that closed on April 21, 2026.
Following the sale, he holds 79,304,460 SBC shares directly, plus 5,000,000 shares indirectly through Aikawa Investment Co., Ltd., a company he wholly owns. He also reports an indirect interest corresponding to 861,600 shares held by Aikawa Equity Management Co., Ltd., while disclaiming beneficial ownership beyond his pecuniary interest.
SBC Medical Group Holdings Incorporated entered into an underwriting agreement for an underwritten secondary offering of 3,100,000 shares of its common stock by CEO and chairman Dr. Yoshiyuki Aikawa as selling stockholder. The underwriters also received a 45-day option to buy up to an additional 465,000 shares.
The offering closed on April 21, 2026. The company did not sell any shares in this transaction and did not receive any proceeds, as all shares were sold by the existing stockholder under its Form S-3 registration statement.
SBC Medical Group Holdings’ major shareholder Yoshiyuki Aikawa sold 3,100,000 shares of common stock in an underwritten secondary offering at $3.0225 per share. The underwriters also received a 45-day option to buy up to 465,000 additional shares. After the offering, Aikawa beneficially owns 84,304,460 shares, or about 82.2% of the 102,576,943 shares outstanding. He entered a 90-day lock-up restricting most additional sales following the April 21, 2026 closing.
SBC Medical Group Holdings Incorporated is registering the resale of 3,100,000 shares of its common stock by the selling stockholder pursuant to this prospectus supplement. The public offering price is $3.25 per share with the selling stockholder receiving the net proceeds; SBC will receive no proceeds. The underwriters have a 45-day option to purchase up to an additional 465,000 shares. Shares outstanding after the offering are stated as 102,576,943 (as of April 16, 2026). The offering is being managed by Maxim Group LLC (book-runner) and Roth Capital Partners (co-manager).
SBC Medical Group Holdings Incorporated discloses a resale offering by a selling stockholder of shares of its common stock; the company states it is not selling any shares hereunder and will receive no proceeds. The prospectus supplement lists a public-market reference price of $4.42 per share (closing price on April 16, 2026) and states there were 102,576,943 shares outstanding as of April 16, 2026. The filing identifies Yoshiyuki Aikawa as the selling stockholder and notes he and entities he controls held approximately 85.2% of voting power as of April 16, 2026. The underwriters have a 45-day option to purchase additional shares; underwriting discounts of 7.0% are disclosed in the underwriting table.
SBC Medical Group Holdings is a Delaware-based holding company that provides management, franchising and support services to aesthetic clinics, primarily in Japan, with operations in Singapore and Vietnam and strategic investments in the United States.
For the years ended December 31, 2025 and 2024, the company generated revenues of $173,607,489 and $205,415,542, respectively, and reported net income of $51,045,023 and $46,689,892. As of December 31, 2025, retained earnings were $240,448,620.
As of December 31, 2025, SBC supported management services for 237 franchisee treatment centers in Japan and operated 21 centers in Singapore and one in Vietnam. In 2024 and 2025 it completed several transactions, including acquiring 100% of Aesthetic Healthcare Holdings in Singapore, MB career lounge in Japan, and a controlling interest in Waqoo, as well as an approximately 18.2% voting interest in OT Midco in the U.S.
The company’s revenues are diversified across franchising, procurement, management services, rental services and other income streams, with franchising revenue of $45,943,241 and procurement revenue of $56,053,171 in 2025. Key risks include dependence on related-party medical corporations, a need for additional capital, international expansion risks, material weaknesses in internal control over financial reporting as of December 31, 2025, and the possibility that Nasdaq may delist its securities.
SBC Medical Group Holdings reported mixed fourth quarter and full-year 2025 results, pairing lower revenue with stronger profitability. Q4 total revenue was $39.6 million, down 11% year over year, but net income attributable to the company rose to $14.2 million and EPS more than doubled to $0.14.
For full-year 2025, revenue declined 15% to $173.6 million, while net income increased 9% to $51.0 million and EPS grew to $0.50. Net income margin expanded to 29%, even as EBITDA fell 21% and EBITDA margin eased to 40%. The company ended the year with $163.8 million in cash and cash equivalents and total assets of $380.4 million.
Management highlighted structural changes in 2024–2025 and revised franchise fee arrangements as key drivers of the revenue decline, while profitability benefited from the absence of prior IPO-related stock-based compensation and impairment charges. SBC also noted improving operating metrics, including 283 franchise locations, 6.6 million customers over the last twelve months, and higher average revenue per customer in Q4.
Alongside the results, SBC posted an investor presentation summarizing its updated business strategy and capital policy, and scheduled a conference call to discuss the quarter and outlook-focused priorities in multi-brand dermatology, non-aesthetic healthcare, and international expansion.
SBC Medical Group Holdings Inc disclosure shows Aikawa Equity Management Co., Ltd. beneficially owns 5,284,500 shares of Common Stock, representing 5.2% of the class. The percentage is based on 102,576,943 shares outstanding as of December 26, 2025. The position arose under a December 23, 2025 subscription agreement; on March 6, 2026 Dr. Yoshiyuki Aikawa ceased to have voting and dispositive power over those shares and the Reporting Person subsequently granted equity interests to certain consultants with redemption rights tied to proceeds from sales of the Reporting Person's Common Stock.